| DB ID | MyCo_3005 |
| Title | In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis |
| Year | 2006 |
| PMID | 16672397 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Culture filtrate sample |
| Sample source | Culture filtrate sample |
| Host Group | None |
| Host Common name | None |
| Host Scientific name | None |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Netherlands |
| Cohort | None |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis (IA) has become a leading cause of death among immunocompromised hosts, including transplant patients, those treated for hematological malignancy, and those treated with high-dose corticosteroids. In addi- tion, IA is increasingly observed in the nonneutropenic phase after hematopoietic stem cell transplantation and in nonclassic settings, such as intensive care units with critically ill patients. The high mortality is due partly to the difficulty in establishing a diagnosis at an early stage of infection, since presenting symptoms are nonspecific and sensitivity of cultures is low. Techniques to improve timely diagnosis have focused on the detection of circulating surrogate markers released by the fungus. With the development of nonculture-based methods, such as PCR and antigen detection, circulating mark-ers can be detected at an early stage of infection in patients with invasive disease. |
| Technique | ELISA |
| Analysis Method | FDA approved Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | PA-Platelia™ Aspergillus Ag ELISA, FDA approved Fungitell assay, Aspergillus PCR |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
